After listening to Qin Yongchuan's introduction, Wu Hao and Zhang Jun nodded involuntarily. If this technology can really be applied, it will definitely benefit many patients and save many lives.

When will this technology be able to enter clinical trials. Zhang Jun still smelled a problem that he was more concerned about.

Qin Yongchuan replied with a smile: "At present, we have completed the technical safety demonstration of this biological drug, and then we will enter animal testing to further test the efficacy and safety of this drug. If there is no problem, we will get the relevant clinical trial approval as soon as possible, and then start the initial clinical trial work.

We plan to use two to three years of clinical trials to fully verify the efficacy and safety of this drug, and then begin to apply for relevant marketing. "

Hearing Qin Yongchuan's answer, Wu Hao nodded with a smile: "In recent years, with the continuous improvement of people's material life, physical health has become the focus of everyone's attention. People are more and more dissatisfied with the current level of medical technology, It is urgent to obtain better medical resources and medical technology services.

Therefore, in recent years, the state has attached great importance to the pharmaceutical industry, and its support has been continuously increased. For some scientific research-oriented medical technology research enterprises, the state has also issued a series of relevant preferential support policies, such as tax relief, scientific research funding subsidies, fund support and a series of measures.

It is to create a good environment for research and development, so that domestic medical technology research enterprises can grow rapidly. Break the monopoly of foreign pharmaceutical giants in the field of cutting-edge pharmaceutical technology, and embark on a new era of scientific research with our own characteristics.

In order to promote the smooth marketing of more and better drugs, provide patients with health services, and save more patients. Relevant departments have also given great support in drug approval.

So regarding this, I suggest you to strengthen the communication and docking with relevant departments, as well as related cooperation. This will help you to carry out related research work, especially a series of work such as clinical trials and subsequent new drug listings.

In this way, our drug for the treatment of Helicobacter pylori has received strong support from relevant departments, and has now entered the approval stage before new drugs are launched. If it goes well, it will be able to pass the approval before this fall and go on the market smoothly. "

Hearing Wu Hao's words, everyone present became excited. You know, this drug has not been developed for a long time, and I did not expect it to be approved and marketed so quickly. This is undoubtedly a great incentive for everyone present, according to the current relevant regulations. All researchers participating in the project will receive a portion of the project's market revenue as dividends. Although no one has a small share, if the market for this technology is good, then they can also get a lot of money.

As far as this new super bacteria drug for treating gastric Helicobacter pylori infection is concerned, according to the curative effect of the current clinical trials, once it is launched, it will definitely be welcomed by the majority of hospitals and patients. If it can be promoted on a large scale, then the researchers involved in the research and development of this drug will be able to share a fairly objective sum of money. That's why everyone present was so surprised and excited when they heard these words.

Surprised by such a short period of time, the excitement is naturally associated with how much their drug will be distributed if it can be marketed.

You can rest assured that we have been maintaining close communication and contact with relevant departments in this regard. It's just that there are still some flaws in this technology at present, so we plan to carefully polish and consider these things. Qin Yongchuan explained to Wu Hao.

When Wu Hao heard Qin Yongchuan's words, he naturally didn't say anything else, and Qin Yongchuan immediately led the crowd to continue to visit.

"The main research work in this area is some basic diseases, although there are some very effective and effective drugs on the market. However, in our opinion, these drugs exist more or less. some problems.

Therefore, we have targeted some diseases and conducted in-depth research to explore whether there are better technologies to apply treatment to obtain better curative effects. Just like the treatment techniques for myopia you have learned earlier, there are many techniques for vision correction on the market, but these are only for people to see things clearly, and they do not completely cure myopia, hyperopia, astigmatism, and strabismus.

So we are exploring whether there is a once and for all way to let people say goodbye to their eyes completely and return to normal vision. At present, our research in this area has made great progress, and this technology will also be ready to enter the clinical trial stage as scheduled.

And here, this is a gastrointestinal drug that we're working on. At present, there are many gastrointestinal drugs, and many drugs have good therapeutic effects on gastrointestinal diseases. However, these drugs also have great side effects and are not suitable for long-term use.

But gastrointestinal disease is a very difficult disease, and it is very easy to turn into a chronic disease. It usually requires a long treatment cycle, and the curative effect is not so significant, and it is very easy to relapse.

In our life, many people suffer from gastrointestinal diseases, some of them are old and sick for several years, more than ten years, or even decades. It is related to the degree of attention and irregular treatment, but also has a great relationship with the current drugs.

For example, many drugs for the treatment of gastrointestinal diseases have a lot of damage to other organs and tissues, such as long-term medication, liver, kidney and other metabolic organs are damaged. It will even cause damage to the gastrointestinal tissue itself. For example, the long-term use of some proton inhibitors may cause some damage to the stomach and increase the risk of cancer. Long-term use of some bismuth, aluminum, and even heavy metals will cause damage to the brain.

So we're exploring if we can have a new drug that has fewer side effects, is milder, and is suitable for long-term use. "

Speaking of this, Qin Yongchuan smiled at everyone: "Maybe many people think that this drug should be very simple, and listed many similar drugs. But in fact, such drugs are very difficult to study.

To develop a drug that is effective for disease, does not harm other organs of the body, and can be reused for a long time, this means that several huge problems of the drug must be solved, so as to obtain a near-perfect drug medicine.

However, in order to achieve this goal, it is easier said than done to develop this perfect drug. "